Frank Litvack's Insider Trades & SAST Disclosures
Frank Litvack's most recent trade in Capricor Therapeutics Inc was a trade of 25,000 Common Stock done at an average price of $1.4 . Disclosure was reported to the exchange on March 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Frank Litvack.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 03 Mar 2025 | 25,000 | 132,382 (2%) | 0% | 1.4 | 34,750 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.67 per share. | 03 Mar 2025 | 2,543 | 129,839 (2%) | 0% | 13.7 | 34,763 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.10 per share. | 02 Dec 2024 | 20,391 | 46,278 (0%) | 0% | 1.1 | 22,430 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2024 | 20,391 | 0 | - | - | Warrants (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2024 | 20,391 | 20,391 | - | - | Warrants (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 20,391 | 0 | - | - | Warrants (Right to Buy) | |
| Capricor Therapeutics Inc | Litvack Frank | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2023 | 20,748 | 0 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 14 Aug 2023 | 20,748 | 137,633 (2%) | 0% | 1.4 | 28,840 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.61 per share. | 14 Aug 2023 | 4,364 | 133,269 (2%) | 0% | 6.6 | 28,846 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 21 Feb 2023 | 14,027 | 141,800 (2%) | 0% | 1.4 | 19,498 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 14,027 | 0 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.31 per share. | 21 Feb 2023 | 4,524 | 137,276 (2%) | 0% | 4.3 | 19,498 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 185,000 | 185,000 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 252,250 | 252,250 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 154,543 | 0 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 03 Jan 2022 | 154,543 | 174,934 (3%) | 3% | 1.4 | 214,815 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 03 Jan 2022 | 67,552 | 107,382 (2%) | 1% | 3.2 | 214,815 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 211,160 | 211,160 | - | - | Stock Option (Right to Buy) | |
| Capricor Therapeutics Inc | Frank Litvack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 280,935 | 280,935 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges